Previous 10 | Next 10 |
Inotiv has largely focused on pre-clinical services that is performed prior to the initiation of any clinical trials in humans. NOTV’s revenue declined by 38% from 2011-2016 and EBITDA turned negative in 2016. Revenue has grown significantly from $20mm in FY ’16 to a...
Headwaters Capital Management is an actively managed, concentrated investment strategy focused on small and mid-capitalization stocks. The Headwaters Capital portfolio declined -10.9% compared to a -5.7% decline for the Russell Mid Cap index in Q1 2022. Similar to last year, I wil...
Citi says investors should still be looking for quality stocks when dealing with the Fed rate hike cycle and a possible recession. "Admittedly, stocks with high-quality attributes have not been immune from this year’s volatility," equity strategist Scott Chronert wrote in a note. "Why?...
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...
Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For the first quarter of 2022, the Aristotle Small/Mid Cap Equity Composi...
Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. For Q1 2022, the Aristotle Small Cap Equity Composite generated a total r...
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Charles River Laboratories International, Inc. 2022 Q1 - Results - Earnings Call Presentation
No Rating Change. Medpace remains an attractive business selling at a discount to its intrinsic value. Management is aggressively repurchasing shares, a signal of confidence and a boost to EPS. For further details see: Medpace Holdings: Update Following Q1 FY2022 Earning...
Charles River Laboratories International, Inc. (CRL) Q1 2022 Earnings Conference Call May 04, 2022 09:30 AM ET Company Participants Todd Spencer - VP, IR James Foster - Chairman, President and CEO Flavia Pease - Interim CFO and EVP David Smith - EVP and CFO Conference Call Participants Eric C...
Charles River Laboratories press release (NYSE:CRL): Q1 Non-GAAP EPS of $2.75 beats by $0.03. Revenue of $913.9M (+10.8% Y/Y) beats by $5.26M. The Company is updating its 2022 financial guidance, which was previously provided on February 16, 2022. Reported revenue growth guidance is being inc...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...